

## Effect of Sex and Estrous Cycle on Nicotine Withdrawal Syndrome in the Rat

Mallori Henceroth, Joseph R Campbell, Mayra Candelario, Joanne Elayoubi, Clarissa L Aguilar and David H Malin\*

Department of Psychology, University of Houston-Clear Lake, 2700 Bay Area Blvd., Houston, Texas, USA

\*Corresponding author: Malin DH, Professor, Department of Psychology, University of Houston-Clear Lake, 2700 Bay Area Blvd., Houston, Texas, UHCL, 2700 Bay Area Blvd, 77058, USA; Tel: 1-281-283-3339; E-mail: malin@uhcl.edu

Received date: July 5, 2018; Accepted date: July 13, 2018; Published date: July 20, 2018

Citation: Henceroth M, Campbell JR, Candelario M, Elayoubi J, Aguilar CL, et al. 2018 Effect of Sex and Estrous Cycle on Nicotine Withdrawal Syndrome in the Rat. J Addict Behav Ther Vol 2 No 2:8.

Copyright: © 2018 Henceroth M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

**Introduction:** Severity of withdrawal syndrome in women during smoking cessation has reportedly been influenced by menstrual phase. There are few studies of female rats with their four-day estrous cycle.

**Methods:** Histological examination determined the precise estrous phase at time of testing. The subjects were 14 qualifying female rats and 8 male rats, all five to six months old. Slides of vaginal fluid were examined for estrous phase-identifying cell types. Nicotine withdrawal was evaluated at either the proestrus phase (n=7), a follicular portion of the cycle, and the metestrus phase (n=7) a luteal portion. Rats were continuously infused with 9 mg/kg/day s.c. nicotine bitartrate. On the seventh day, each subject was challenged with 1 mg/kg of the nicotinic antagonist mecamylamine, a dose that precipitates a vigorous withdrawal syndrome only in nicotine-dependent rats. Subjects were observed over 30 min. on a standard checklist of somatically expressed withdrawal behaviors.

**Results:** Male rats displayed  $26.00 \pm 3.64$  withdrawal signs ( $M \pm SEM$ ), while female rats in proestrus exhibited a similar  $28.86 \pm 3.39$  signs. Female rats in metestrus displayed  $41.57 \pm 5.38$  signs. One-way ANOVA revealed a significant difference among groups,  $p=0.039$ . Post hoc comparisons revealed significant differences between metestrus and proestrus females,  $p=0.049$  and between metestrus females and males,  $p=0.016$ , but not between proestrus females and males.

**Conclusions:** The results are consistent with reports of menstrual phase influence on withdrawal severity in smoking cessation, providing a laboratory model for studying this issue and its potential treatment.

**Implications:** In the large literature on nicotine withdrawal in the rat, there are relatively few studies on female rats and hardly any on the effects of the estrous cycle on physical dependence and withdrawal. The results are consistent with reports on the menstrual cycle affecting withdrawal severity in women undergoing smoking cessation, supporting the translational relevance of the rat

nicotine dependence model. The methods utilized here expand the ability of rat physical dependence models to compare the sexes and the estrous phases in nicotine physical dependence and withdrawal.

**Keywords:** Nicotine withdrawal; Sex; Estrous cycle; Luteal phase; Follicular phase

### Introduction

Women have been reported to have higher average difficulty than men in smoking cessation [1-4]. There are also some gender differences in effectiveness of some smoking cessation treatments [5-7]. Such gender differences might plausibly be affected by the estrous or menstrual cycle [8,9].

The estrous cycle is divided into four phases [10]. The proestrus and estrus phases constitute the follicular phase, distinguished by maturation and release of the ovum and peaks in serum estrogen and progesterone. The metestrus and diestrus phases featuring uterine implantation of the ovum, facilitated by progesterone from the ovarian corpus luteum [10].


Meta-analyses [10,11] supported earlier suggestions [12-15] that women undergoing smoking cessation experience a more severe withdrawal syndrome in their luteal phase. It would be useful if this sort of phenomenon treatments could be produced in the animal laboratory. This would allow detailed study of its biological mechanisms and its modulation by experimental treatments. The present study determined the effects of sex and estrous cycle on intensity of nicotine withdrawal syndrome in the rat. It was hypothesized that female rats in metestrus would display more withdrawal signs than females in proestrus. These two phases were chosen because of the contrast between peaks of estrogen and progesterone levels during proestrus and much lower levels of each during metestrus [16]. Another hypothesis was that withdrawal signs in male rats would differ more from metestrus females than from proestrus females.

## Methods

Subjects included sixteen female five to 6-month-old Sprague-Dawley rats housed in two large cages with eight each to synchronize their estrous cycles. Eight male Sprague-Dawley rats of the same age were housed together. Experimental procedures accorded with the National Institutes of Health Guide for Care and Use of Laboratory Animals.

### Determination of estrous cycle phase

Prior to nicotine infusion, vaginal smears were taken each morning for eight days, thereby completing collection of two four day cycles [17]. Vaginal fluid was collected with a micropipette filled with 40  $\mu$ L of isotonic saline inserted into the tip of the vagina, and flushed until cloudy. Vaginal fluid was placed on a glass slide, one drop of 0.5% methylene blue stain was added, and photomicroscopic images were taken (**Figure 1**). All female rats were determined to be in the same estrous cycle phase prior to nicotine infusion. During nicotine infusion, cycle phases were checked daily to ensure consistency of the rats' estrous cycle. Vaginal smears were again examined immediately following observations for precipitated withdrawal, ensuring that females were in the predicted estrous cycle phase during withdrawal observation. Two female rats were disqualified from the study because the expected estrous phase was not confirmed in one of the smears.



**Figure 1.** Vaginal smears (30X) indicative of four estrous phases in the rat.

(I) The proestrus phase of the estrous cycle is typically free of leukocytes and contains nucleated epithelial (round, nucleated) cells. (II) The estrus phase is typically free of leukocytes and contains cornified (irregularly shaped) epithelial cells. (III) The metestrus phase contains leukocytes (very small cells) and cornified epithelial cells. (IV) The diestrus phase contains leukocytes, like the metestrus phase. However, it can be differentiated from metestrus by the vacuolated (hollow) and nucleated epithelial cells characteristic of the phase.

### Nicotine dependence and precipitated withdrawal

A 2ML1 osmotic minipump was subcutaneously implanted in the shoulder region of each rat under isoflurane anesthesia. The pumps released nicotine bitartrate at a constant rate of 9 mg/kg per day for seven days, resulting in similar nicotine blood concentration levels to those of heavy smokers [18].

There were three groups: eight male rats used as a comparison group, seven female rats implanted during their estrus phase so that they should be in proestrus at the end of infusion, and seven female rats implanted during the diestrus phase so they should be in metestrus at the end of infusion. Examination of vaginal smears determined each rat's estrous phase immediately after observations.

To precipitate withdrawal, each rat was injected with 1 mg/kg of mecamylamine, a noncompetitive nicotinic receptor antagonist [18]. This dose induces a withdrawal syndrome only in nicotine-dependent rats [19]. Thus, number of occurrences of withdrawal signs reflect the severity of nicotine dependence. Immediately after injection, rats were observed under "blind" conditions over 30 min. on a standard checklist of nicotine withdrawal behaviors (shakes/tremors, writhes/gasps, teeth chatters/vacuous chews, ptosis and miscellaneous less frequently observed signs: genital licks, hind foot scratches, backing up, and attempted escape jumps out of the observation chamber). Because tremors, chews and ptosis can sometimes continue for relatively long periods, continuous bouts of tremors and chews were not counted more often than once every 15 sec, and ptosis was not counted more often than once every 60 sec. Studies have supported the validity of overall numbers of these signs as an indicator of nicotine withdrawal severity [18,20].


## Results

Males exhibited  $26.00 \pm 3.64$  ( $M \pm SEM$ ) overall signs. Females in proestrus exhibited  $28.86 \pm 3.39$  signs. In contrast, female rats in metestrus displayed  $41.57 \pm 5.38$  signs. One-way ANOVA of overall withdrawal signs indicated a significant difference among the groups,  $F(2,19)=3.885$ ,  $p=0.039$ .

Post hoc analysis (Fischer's LSD test) revealed that females in the metestrus phase exhibited significantly more total signs than females in the proestrus phase,  $p=0.049$ , and than males,  $p=0.016$ , which exhibited  $26.44 \pm 3.24$  ( $M \pm SEM$ ) signs (**Figure 2**). The difference between females in the proestrus phase and males was not significant,  $p=0.632$ .

As shown in **Table 1**, female subjects in metestrus exhibited more signs than the other groups in all individual categories, except ptosis. Post hoc analysis (Fischer's LSD test) revealed that metestrus females exhibited significantly more vacuous chews than proestrus females,  $p=0.025$ .

Metestrus females had significantly more miscellaneous, less frequently observed signs than females in proestrus,  $p=0.047$ , while their difference from males approached significance,  $p=0.060$ .



**Figure 2.** A one-way ANOVA indicated significance differences among groups in the number of total withdrawal signs exhibited. \* $p=0.02$  vs. proestrus \*\* $p=0.007$  vs. males.

There were no other significant group differences in individual categories of withdrawal signs.

**Table 1.** Occurrences of Individual categories of withdrawal signs ( $M \pm SEM$ ).

1 $p=0.025$  vs. proestrus, 2 $p=0.047$  vs. proestrus and 0.06 vs. male (Tukey's HSD test).

Sign	Male	Proestrus	Metestrus
Writhes/Gasps	14.87 $\pm$ 2.84	19.43 $\pm$ 2.36	22.14 $\pm$ 4.52
Shakes/Tremors	4.75 $\pm$ 1.49	4.43 $\pm$ 1.74	7.00 $\pm$ 1.98
Chews	3.37 $\pm$ 0.625	1.29 $\pm$ 0.68	4.86 $\pm$ 1.551
Ptosis	1.88 $\pm$ 1.47	2.42 $\pm$ 0.78	1.0 $\pm$ 0.53
Miscellaneous	1.62 $\pm$ 0.65	1.14 $\pm$ 0.40	6.57 $\pm$ 3.092

## Discussion

Previous studies with this model of rodent nicotine dependence have mostly been conducted with male rats. However it is increasingly clear that continuous subcutaneous infusion can induce considerable nicotine dependence in female Sprague Dawley rats. This was earlier shown by spontaneous withdrawal syndrome [21,22], and is now confirmed by antagonist-precipitated withdrawal in the present study. The results further suggest that females in the luteal phase, are more susceptible to severe nicotine withdrawal syndrome than females in the follicular phase and than males. The severity of withdrawal was not significantly different between male rats and females in the follicular phase. The results are consistent with clinical research on smoking cessation in women, suggesting more severe withdrawal in the luteal than the follicular phase [8,11,14,15]. Escape jumps are a withdrawal sign of particular interest because it has been commonly reported in morphine-abstinent mice [23] and not in nicotine-abstinent rats.

Males showed absolutely no escape jump behavior, whereas females in the luteal phase had many occurrences of this severe withdrawal sign, suggestive of a panic reaction. Females in metestrus exhibited a mean of 3.71 escape jumps compared to 0.28 escape jumps shown by females in proestrus.

The four day rat estrous cycle has led many researchers to avoid using female subjects for fear of increased behavioral variability. This sort of situation may create sex bias in the research literature, resulting in potential limitations of applicability to public health [24]. In situations where this is a concern, it can be dealt with by taking estrous cycle phases into account, as in the present experiment. If a research plan calls for making the two sexes more comparable, it may be advantageous to use females in the follicular phase. However, in preclinical drug research, it may be valuable to also study the luteal phase with increased its high progesterone and its potential influence on dependence and withdrawal syndrome [11].

The present data provide additional evidence for translational relevance of rodent nicotine dependence models [18-20] to phenomena observed in human smokers [11]. However, in addition to withdrawal severity, the human estrous cycle may affect other variables relevant to smoking cessation. For example, estrous phase may alter subjective response to and craving for nicotine [25,26].

The present results open up possibilities for future research to determine effects of estrous phase on additional measures of nicotine withdrawal severity, such as conditioned place aversion, intracerebral self-stimulation threshold or the anxiety response in the elevated plus-maze. Further research directions might include assessing the other two phases (estrus and diestrus) within the follicular and luteal portions of the cycle. In addition, the effect of estrous phase at the onset of drug exposure could be studied for any influence on initial dependence formation. It would also be interesting to determine the effects of direct separate and combined progesterone or estradiol administration on nicotine dependence and withdrawal syndrome.

## Conclusion

The animal laboratory results further confirm the interaction between sex and the estrous cycle in modulating nicotine dependence and withdrawal. The results also suggest a rapid and efficient laboratory model to study the biological basis and experimental treatment of this phenomenon.

## Funding

The authors are grateful to the University of Houston-Clear Lake Faculty Research Support Fund for financing this study. The fund had no involvement in the design, conduct and reporting of the research.

## Author's Contribution

MH and DM conceived the study. All authors participated in experiments, data collection, and analysis. All authors have also contributed to and approved the final manuscript.

## Conflict of Interest

No authors had any conflict of interest.

## Acknowledgements

Thanks to Dr. Richard Puzdrowski, UHCL, for assistance with photomicrography. The authors appreciate experimental assistance from Michael Meriano, Caitlin Madison, and Angela Romine.

## References

1. Bohadana A, Nilsson F, Rasmussen T, Martinet Y (2003) Gender differences in quit rates following smoking cessation with combination nicotine therapy: influence of baseline smoking behavior. *Nicotine Tob Res* 5: 111-116.
2. Royce JM, Corbett K, Sorensen G, Ockene J (1997) Gender, social pressure, and smoking cessations: The Community Intervention Trial for Smoking Cessation (COMMIT) at baseline. *Soc Sci Med* 44: 359-370.
3. Ward KD, Klesges RC, Zbikowski SM, Bliss RE, Garvey AJ (1997) Gender differences in the outcome of an unaided smoking cessation attempt. *Addict Behav* 22: 521-533.
4. Wetter DW, Kenford SL, Smith SS, Fiore MC, Jorenby DE, et al. (1999) Gender differences in smoking cessation. *J Consult Clin Psychol* 67: 555-562.
5. McKee SA, Smith PH, Kaufman M, Mazure CM, Weinberger AH (2015) Sex differences in Varenicline efficacy for smoking cessation: a meta-analysis. *Nicotine Tob Res* 18: 1002-1011.
6. McKee SA, Weinberger AH (2015) Innovations in translational sex and gender-sensitive tobacco research. *Nicotine Tob Res* 17: 379-381.
7. Verplaetse TL, Weinberger AH, Smith PH, Cosgrove KP, Mineur YS (2015) Targeting the noradrenergic system for gender-sensitive medication development for tobacco dependence. *Nicotine Tob Res* 17: 486-495.
8. Carpenter MJ, Upadhyaya HP, LaRowe SD, Saladin ME, Brady KT (2006) Menstrual cycle phase effects on nicotine withdrawal and cigarette craving: a review. *Nicotine Tob Res* 8: 627-638.
9. Carpenter MJ, Saladin ME, Leinbach AS, Larowe SD, Upadhyaya HP (2008) Menstrual phase effects on smoking cessation: a pilot feasibility study. *J Womens Health* 17: 293-301.
10. Marcondes F, Bianchi F, Tanno A (2002) Determination of the estrous cycle phases of rats: some helpful considerations. *Braz J Biol* 62: 609-614.
11. Weinberger AH, Smith PH, Allen SS, Cosgrove KP, Saladin ME, et al. (2015) Systematic and meta-analytic review of research examining the impact of menstrual cycle phase and ovarian hormones on smoking and cessation. *Nicotine Tob Res* 17: 407-421.
12. Allen SS, Hatsukami DK, Christianson D, Nelson D (1999) Withdrawal and pre-menstrual symptomology during the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smoking abstinence. *Nicotine Tob Res* 1: 129-142.
13. Allen SS, Hatsukami D, Christianson D, Brown S (2000) Effects of transdermal nicotine on craving, withdrawal and premenstrual symptomology in short-term smoking abstinence during difference phases of the menstrual cycle. *Nicotine Tob Res* 2: 231-241.
14. O'Hara P, Portser SA, Anderson BP (1989) The influence of menstrual cycle changes on the tobacco withdrawal syndrome in women. *Addict Behav* 14: 595-600.
15. Perkins KA, Levine M, Marcus M, Shiffman S, D'Amico D, et al. (2000) Tobacco withdrawal in women and menstrual cycle phase. *J Consult Clin Psychol* 68: 176-180.
16. Becker JB, Arnold A, Berkley K, Blaustein J, Eckel L, et al. (2005) Strategies and methods for research on sex differences in brain and behavior. *Endocrinology* 146: 1650-1673.
17. Goldman JM, Murr AS, Cooper LR (2007) The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicology studies. *Birth Defects Res B Dev Reprod Toxicol* 80: 84-97.
18. Malin D, Goyarzu P (2009) Rodent models of nicotine withdrawal syndrome. *Handb Exp Pharmacol* 192: 401-434.
19. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, et al. (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. *Psychopharmacology* 115: 180-184.
20. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, et al. (1992) Rodent model of nicotine abstinence syndrome. *Pharmacol Biochem Behav* 43: 779-784.
21. Hamilton KR, Perry ME, Berger SS, Grunberg NE (2010) Behavioral effects of nicotine withdrawal differs by genetic strain in male and female adolescent rats. *Nicotine Tob Res* 12: 1236-1245.
22. Hamilton KR, Perry ME, Berger SS, Grunberg NE (2009) Behavioral effects of nicotine withdrawal in adult male and female rats. *Pharmacol Biochem Behav* 92: 51-59.
23. Blanchard C, Griebel G, Blanchard R (2001) Mouse defensive behaviors: pharmacological and behavioral assays for anxiety and panic. *Neurosci Biobehav Rev* 25: 205-218.
24. Clayton JA, Collins FS (2014) NIH to balance sex in cell and animal studies. *Nature* 509: 282-283.
25. Allen AM, Allen SS, Widenmier J, Al'absi M (2009) Patterns of cortisol and craving by menstrual phase in women attempting to quit smoking. *Addiction* 104: 632-635.
26. Sofuoglu M, Babb DA, Hatsukami DK (2001) Progesterone treatment during the early follicular phase of the menstrual cycle: effects of smoking behavior in women. *Pharmacol Biochem Behav* 69: 299-304.